The cardioprotective effects of SGLT2 inhibitors via renal-heart related factors

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07103
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47040:Pharmacology-related
• Research Institution: Saitama Medical University
• Principal Investigator: Sugi Keiki 埼玉医科大学, 医学部, 講師 (70792977)
• Co-Investigator(Kenkyū-buntansha): 水野 洋介 埼玉医科大学, 医学部, 准教授 (30406532) ; 山田 良大 埼玉医科大学, 医学部, 講師 (40792982) ; 中埜 信太郎 埼玉医科大学, 医学部, 教授 (60307387) ; 千本松 孝明 埼玉医科大学, 医学部, 教授 (70216563)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 慢性心不全 / 2型糖尿病 / SGLT2阻害薬 / 腎心連関

Outline of Final Research Achievements

The prognosis for heart failure patients is worse, with a 5-year survival rate in the 50% range. In this context, it was reported that SGLT (sodium/glucose cotransporter) 2 inhibitors, a diabetes drug that acts in the kidney, exert cardioprotective effects in diabetes-complicated heart failure (N Engl J Med. 2015). To answer the question of why SGLT2 inhibition in the proximal tubules of the kidney produces organ-protective effects in the remote heart, research was initiated and normal and diabetic tubular models were used. PCR and digital PCR were performed to confirm the cellular characteristics, but the experiment was unsuccessful because no expression of the key SGLT2 inhibitor was observed.

Free Research Field

循環器領域

Academic Significance and Societal Importance of the Research Achievements

SGLT2阻害薬は最近になり、非糖尿病の心不全患者にも死亡率や再入院率を低下させることが報告（N Engl J Med.381:1995-2008. 2019)され始めており心臓、腎臓の両方に対しては良い効果があることは間違いないが実際の機序は未だにわかっていない。この研究の目的は、腎心連関の機序の解明であったが残念ながら尿細管上皮細胞にSGLT2交抗体の発現が認められず研究を進めることが困難であった。